Credit Suisse’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $1.87M | Buy |
117,399
+8,859
| +8% | +$133K | ﹤0.01% | 1900 |
|
|
2023
Q4 | $1.82M | Buy |
108,540
+436
| +0.4% | +$5.96K | ﹤0.01% | 1956 |
|
|
2023
Q3 | $1.26M | Sell |
108,104
-33,724
| -24% | -$451K | ﹤0.01% | 2142 |
|
|
2023
Q2 | $1.91M | Buy |
141,828
+56,228
| +66% | +$809K | ﹤0.01% | 1943 |
|
|
2023
Q1 | $1.42M | Buy |
85,600
+2,349
| +3% | +$38.8K | ﹤0.01% | 2086 |
|
|
2022
Q4 | $1.55M | Buy |
83,251
+1,805
| +2% | +$27.8K | ﹤0.01% | 2034 |
|
|
2022
Q3 | $1.04M | Buy |
81,446
+12,138
| +18% | +$144K | ﹤0.01% | 2304 |
|
|
2022
Q2 | $486K | Sell |
69,308
-2,887
| -4% | -$21.2K | ﹤0.01% | 2861 |
|
|
2022
Q1 | $598K | Sell |
72,195
-1,877
| -3% | -$13.3K | ﹤0.01% | 2869 |
|
|
2021
Q4 | $501K | Buy |
74,072
+3,047
| +4% | +$20K | ﹤0.01% | 3820 |
|
|
2021
Q3 | $376K | Buy |
71,025
+6,868
| +11% | +$37.6K | ﹤0.01% | 3986 |
|
|
2021
Q2 | $369K | Sell |
64,157
-22,481
| -26% | -$116K | ﹤0.01% | 4008 |
|
|
2021
Q1 | $399K | Sell |
86,638
-106,906
| -55% | -$425K | ﹤0.01% | 3893 |
|
|
2020
Q4 | $646K | Sell |
193,544
-112,569
| -37% | -$378K | ﹤0.01% | 3651 |
|
|
2020
Q3 | $910K | Buy |
306,113
+10,480
| +4% | +$41K | ﹤0.01% | 3004 |
|
|
2020
Q2 | $1.37M | Sell |
295,633
-24,327
| -8% | -$109K | ﹤0.01% | 2683 |
|
|
2020
Q1 | $1.23M | Sell |
319,960
-242,113
| -43% | -$994K | ﹤0.01% | 2487 |
|
|
2019
Q4 | $2.11M | Buy |
562,073
+505,667
| +896% | +$2.36M | ﹤0.01% | 2561 |
|
|
2019
Q3 | $300K | Buy |
56,406
+8,861
| +19% | +$47.2K | ﹤0.01% | 3700 |
|
|
2019
Q2 | $182K | Buy |
47,545
+26,181
| +123% | +$113K | ﹤0.01% | 3863 |
|
|
2019
Q1 | $110K | Buy |
21,364
+6,365
| +42% | +$18.7K | ﹤0.01% | 3837 |
|
|
2018
Q4 | $29K | Buy |
+14,999
| New | +$42.9K | ﹤0.01% | 3827 |
|
|
2018
Q3 | – | Sell |
-25,048
| Closed | -$78K | – | 3809 |
|
|
2018
Q2 | $78K | Sell |
25,048
-6,035
| -19% | -$18.3K | ﹤0.01% | 3860 |
|
|
2018
Q1 | $75K | Buy |
31,083
+9,456
| +44% | +$31.4K | ﹤0.01% | 3844 |
|
|
2017
Q4 | $84K | Sell |
21,627
-26,077
| -55% | -$86.2K | ﹤0.01% | 3856 |
|
|
2017
Q3 | $120K | Buy |
47,704
+33,725
| +241% | +$92.5K | ﹤0.01% | 4060 |
|
|
2017
Q2 | $38K | Sell |
13,979
-2,071
| -13% | -$4.32K | ﹤0.01% | 3796 |
|
|
2017
Q1 | $31K | Buy |
16,050
+45
| +0.3% | +$57 | ﹤0.01% | 3762 |
|
|
2016
Q4 | $17K | Sell |
16,005
-127,846
| -89% | -$146K | ﹤0.01% | 4064 |
|
|
2016
Q3 | $157K | Sell |
143,851
-281,225
| -66% | -$253K | ﹤0.01% | 3862 |
|
|
2016
Q2 | $302K | Buy |
425,076
+326,948
| +333% | +$263K | ﹤0.01% | 3686 |
|
|
2016
Q1 | $115K | Buy |
98,128
+41,700
| +74% | +$64.7K | ﹤0.01% | 3808 |
|
|
2015
Q4 | $137K | Buy |
56,428
+21,741
| +63% | +$62.3K | ﹤0.01% | 4019 |
|
|
2015
Q3 | $104K | Sell |
34,687
-4,412
| -11% | -$19K | ﹤0.01% | 4093 |
|
|
2015
Q2 | $162K | Sell |
39,099
-121,070
| -76% | -$483K | ﹤0.01% | 4288 |
|
|
2015
Q1 | $693K | Buy |
160,169
+95,260
| +147% | +$343K | ﹤0.01% | 3296 |
|
|
2014
Q4 | $193K | Buy |
64,909
+19,525
| +43% | +$53.6K | ﹤0.01% | 4281 |
|
|
2014
Q3 | $151K | Buy |
+45,384
| New | +$119K | ﹤0.01% | 4225 |
|
|
2013
Q3 | – | Sell |
-13,899
| Closed | -$12K | – | 4220 |
|
|
2013
Q2 | $12K | Buy |
+13,899
| New | +$11.1K | ﹤0.01% | 4147 |
|
Other funds holding CPRX
DM
RA
Credit Suisse's CPRX Position: Q1 2024 in Review
Credit Suisse increased its Catalyst Pharmaceutical (CPRX) stake by 8.2% in Q1 2024, buying an estimated $133K and bringing the position to 117,399 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1900.
Credit Suisse first reported a position in CPRX in Q2 2013 and has held it in 39 quarters since. The position peaked at $2.11M in Q4 2019. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.
- Credit Suisse held 117,399 shares of Catalyst Pharmaceutical worth $1.87M as of Q1 2024.
- Credit Suisse bought 8,859 Catalyst Pharmaceutical shares in Q1 2024, an estimated $133K.
- Catalyst Pharmaceutical made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1900 holding.
- Credit Suisse first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 39 quarters since.
- Credit Suisse's Catalyst Pharmaceutical position peaked at $2.11M in Q4 2019.
- 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.